Gene Review:
MDM2 - MDM2 proto-oncogene, E3 ubiquitin protein...
Homo sapiens
Synonyms:
ACTFS, Double minute 2 protein, E3 ubiquitin-protein ligase Mdm2, HDM2, HDMX, ...
Ying Cui,
Yan Shen,
Hao Yang,
Paul,
Vlatkovic,
Sardet,
Gangqiao Zhou,
Boyd,
Weber,
Hongxing Zhang,
Julien,
Boqing Qiang,
Baudis,
Xiaojia Dong,
Linares,
Rodriguez,
Lianteng Zhi,
Reifenberger,
Fuchu He,
Triboulet,
Xiaoyan Yuan,
Lichter,
Shmueli,
Xiumei Zhang,
Woods,
Zhou,
Findley,
Jiang,
Boström,
Lacroix,
Bossis,
Collins,
Yun Zhai,
Le Cam,
Kaitai Yao,
Hatchi,
Coux,
Xiaoai Zhang,
Ying He,
Wolter,
Gu,
Maki,
Haines,
Wei Qiu,
- Interaction between the retinoblastoma protein and the oncoprotein MDM2. Xiao, Z.X., Chen, J., Levine, A.J., Modjtahedi, N., Xing, J., Sellers, W.R., Livingston, D.M. Nature (1995)
- MDM2 gene amplification and transcript levels in human sarcomas: relationship to TP53 gene status. Flørenes, V.A., Maelandsmo, G.M., Forus, A., Andreassen, A., Myklebost, O., Fodstad, O. J. Natl. Cancer Inst. (1994)
- Antisense therapy targeting MDM2 oncogene in prostate cancer: Effects on proliferation, apoptosis, multiple gene expression, and chemotherapy. Zhang, Z., Li, M., Wang, H., Agrawal, S., Zhang, R. Proc. Natl. Acad. Sci. U.S.A. (2003)
- The tumor suppressor p53 and the oncoprotein simian virus 40 T antigen bind to overlapping domains on the MDM2 protein. Brown, D.R., Deb, S., Muñoz, R.M., Subler, M.A., Deb, S.P. Mol. Cell. Biol. (1993)
- MDM2 protein overexpression promotes proliferation and survival of multiple myeloma cells. Teoh, G., Urashima, M., Ogata, A., Chauhan, D., DeCaprio, J.A., Treon, S.P., Schlossman, R.L., Anderson, K.C. Blood (1997)
- MDM2 promoter SNP309 is associated with risk of occurrence and advanced lymph node metastasis of nasopharyngeal carcinoma in Chinese population. Zhou, G., Zhai, Y., Cui, Y., Zhang, X., Dong, X., Yang, H., He, Y., Yao, K., Zhang, H., Zhi, L., Yuan, X., Qiu, W., Zhang, X., Shen, Y., Qiang, B., He, F. Clin. Cancer Res. (2007)
- MDM2 SNP309 polymorphism as risk factor for susceptibility and poor prognosis in renal cell carcinoma. Hirata, H., Hinoda, Y., Kikuno, N., Kawamoto, K., Suehiro, Y., Tanaka, Y., Dahiya, R. Clin. Cancer Res. (2007)
- MDM2 promoter polymorphism and pancreatic cancer risk and prognosis. Asomaning, K., Reid, A.E., Zhou, W., Heist, R.S., Zhai, R., Su, L., Kwak, E.L., Blaszkowsky, L., Zhu, A.X., Ryan, D.P., Christiani, D.C., Liu, G. Clin. Cancer Res. (2008)
- A novel functional polymorphism C1797G in the MDM2 promoter is associated with risk of bladder cancer in a Chinese population. Wang, M., Zhang, Z., Zhu, H., Fu, G., Wang, S., Wu, D., Zhou, J., Wei, Q., Zhang, Z. Clin. Cancer Res. (2008)
- NEDD4-1 Is a Proto-Oncogenic Ubiquitin Ligase for PTEN. Wang, X., Trotman, L.C., Koppie, T., Alimonti, A., Chen, Z., Gao, Z., Wang, J., Erdjument-Bromage, H., Tempst, P., Cordon-Cardo, C., Pandolfi, P.P., Jiang, X. Cell (2007)
- A novel role for high-mobility group a proteins in cellular senescence and heterochromatin formation. Narita, M., Narita, M., Krizhanovsky, V., Nuñez, S., Chicas, A., Hearn, S.A., Myers, M.P., Lowe, S.W. Cell (2006)
- E4F1 Is an Atypical Ubiquitin Ligase that Modulates p53 Effector Functions Independently of Degradation. Le Cam, L., Linares, L.K., Paul, C., Julien, E., Lacroix, M., Hatchi, E., Triboulet, R., Bossis, G., Shmueli, A., Rodriguez, M.S., Coux, O., Sardet, C. Cell (2006)
- hnRNP K: an HDM2 target and transcriptional coactivator of p53 in response to DNA damage. Moumen, A., Masterson, P., O'Connor, M.J., Jackson, S.P. Cell (2005)
- A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans. Bond, G.L., Hu, W., Bond, E.E., Robins, H., Lutzker, S.G., Arva, N.C., Bargonetti, J., Bartel, F., Taubert, H., Wuerl, P., Onel, K., Yip, L., Hwang, S.J., Strong, L.C., Lozano, G., Levine, A.J. Cell (2004)
- PTEN reverses MDM2-mediated chemotherapy resistance by interacting with p53 in acute lymphoblastic leukemia cells. Zhou, M., Gu, L., Findley, H.W., Jiang, R., Woods, W.G. Cancer Res. (2003)
- Combined targeting of epidermal growth factor receptor and MDM2 by gefitinib and antisense MDM2 cooperatively inhibit hormone-independent prostate cancer. Bianco, R., Caputo, R., Caputo, R., Damiano, V., De Placido, S., Ficorella, C., Agrawal, S., Bianco, A.R., Ciardiello, F., Tortora, G. Clin. Cancer Res. (2004)
- MDM2 enhances the function of estrogen receptor alpha in human breast cancer cells. Saji, S., Okumura, N., Eguchi, H., Nakashima, S., Suzuki, A., Toi, M., Nozawa, Y., Saji, S., Hayashi , S. Biochem. Biophys. Res. Commun. (2001)
- Flavopiridol induces apoptosis in glioma cell lines independent of retinoblastoma and p53 tumor suppressor pathway alterations by a caspase-independent pathway. Alonso, M., Tamasdan, C., Miller, D.C., Newcomb, E.W. Mol. Cancer Ther. (2003)
- Genistein, a dietary isoflavone, down-regulates the MDM2 oncogene at both transcriptional and posttranslational levels. Li, M., Zhang, Z., Hill, D.L., Chen, X., Wang, H., Zhang, R. Cancer Res. (2005)
- DNA damage-induced phosphorylation of p53 alleviates inhibition by MDM2. Shieh, S.Y., Ikeda, M., Taya, Y., Prives, C. Cell (1997)
- Rescue of embryonic lethality in Mdm4-null mice by loss of Trp53 suggests a nonoverlapping pathway with MDM2 to regulate p53. Parant, J., Chavez-Reyes, A., Little, N.A., Yan, W., Reinke, V., Jochemsen, A.G., Lozano, G. Nat. Genet. (2001)
- p300/MDM2 complexes participate in MDM2-mediated p53 degradation. Grossman, S.R., Perez, M., Kung, A.L., Joseph, M., Mansur, C., Xiao, Z.X., Kumar, S., Howley, P.M., Livingston, D.M. Mol. Cell (1998)
- Oncogene amplification in urothelial cancers with p53 gene mutation or MDM2 amplification. Habuchi, T., Kinoshita, H., Yamada, H., Kakehi, Y., Ogawa, O., Wu, W.J., Takahashi, R., Sugiyama, T., Yoshida, O. J. Natl. Cancer Inst. (1994)
- Ribosomal protein L23 activates p53 by inhibiting MDM2 function in response to ribosomal perturbation but not to translation inhibition. Dai, M.S., Zeng, S.X., Jin, Y., Sun, X.X., David, L., Lu, H. Mol. Cell. Biol. (2004)
- Cul4A physically associates with MDM2 and participates in the proteolysis of p53. Nag, A., Bagchi, S., Raychaudhuri, P. Cancer Res. (2004)
- MDM2 mediates p300/CREB-binding protein-associated factor ubiquitination and degradation. Jin, Y., Zeng, S.X., Lee, H., Lu, H. J. Biol. Chem. (2004)
- p53 stabilization and functional impairment in the absence of genetic mutation or the alteration of the p14(ARF)-MDM2 loop in ex vivo and cultured adult T-cell leukemia/lymphoma cells. Takemoto, S., Trovato, R., Cereseto, A., Nicot, C., Kislyakova, T., Casareto, L., Waldmann, T., Torelli, G., Franchini, G. Blood (2000)
- The p53-binding protein MDM2 gene is differentially expressed in human breast carcinoma. Sheikh, M.S., Shao, Z.M., Hussain, A., Fontana, J.A. Cancer Res. (1993)
- The epithelial cell transforming sequence 2, a guanine nucleotide exchange factor for Rho GTPases, is repressed by p53 via protein methyltransferases and is required for G1-S transition. Scoumanne, A., Chen, X. Cancer Res. (2006)
- p14ARF silencing by promoter hypermethylation mediates abnormal intracellular localization of MDM2. Esteller, M., Cordon-Cardo, C., Corn, P.G., Meltzer, S.J., Pohar, K.S., Watkins, D.N., Capella, G., Peinado, M.A., Matias-Guiu, X., Prat, J., Baylin, S.B., Herman, J.G. Cancer Res. (2001)
- ARF promotes MDM2 degradation and stabilizes p53: ARF-INK4a locus deletion impairs both the Rb and p53 tumor suppression pathways. Zhang, Y., Xiong, Y., Yarbrough, W.G. Cell (1998)
- Repression of p53-mediated transcription by MDM2: a dual mechanism. Thut, C.J., Goodrich, J.A., Tjian, R. Genes Dev. (1997)
- A novel cellular protein (MTBP) binds to MDM2 and induces a G1 arrest that is suppressed by MDM2. Boyd, M.T., Vlatkovic, N., Haines, D.S. J. Biol. Chem. (2000)
- Ligand-dependent interaction of the glucocorticoid receptor with p53 enhances their degradation by Hdm2. Sengupta, S., Wasylyk, B. Genes Dev. (2001)
- Stabilization of the MDM2 oncoprotein by interaction with the structurally related MDMX protein. Sharp, D.A., Kratowicz, S.A., Sank, M.J., George, D.L. J. Biol. Chem. (1999)
- Ribosomal protein S7 as a novel modulator of p53-MDM2 interaction: binding to MDM2, stabilization of p53 protein, and activation of p53 function. Chen, D., Zhang, Z., Li, M., Wang, W., Li, Y., Rayburn, E.R., Hill, D.L., Wang, H., Zhang, R. Oncogene (2007)
- Rapid ATM-dependent phosphorylation of MDM2 precedes p53 accumulation in response to DNA damage. Khosravi, R., Maya, R., Gottlieb, T., Oren, M., Shiloh, Y., Shkedy, D. Proc. Natl. Acad. Sci. U.S.A. (1999)
- Oligomerization is required for p53 to be efficiently ubiquitinated by MDM2. Maki, C.G. J. Biol. Chem. (1999)
- A 60 kd MDM2 isoform is produced by caspase cleavage in non-apoptotic tumor cells. Pochampally, R., Fodera, B., Chen, L., Shao, W., Levine, E.A., Chen, J. Oncogene (1998)
- Neddylating the guardian; Mdm2 catalyzed conjugation of Nedd8 to p53. Harper, J.W. Cell (2004)
- Accumulation of soluble and nucleolar-associated p53 proteins following cellular stress. Klibanov, S.A., O'Hagan, H.M., Ljungman, M. J. Cell. Sci. (2001)
- MDM2 is a negative regulator of p21WAF1/CIP1, independent of p53. Zhang, Z., Wang, H., Li, M., Agrawal, S., Chen, X., Zhang, R. J. Biol. Chem. (2004)
- Two arginine rich domains in the p14ARF tumour suppressor mediate nucleolar localization. Rizos, H., Darmanian, A.P., Mann, G.J., Kefford, R.F. Oncogene (2000)
- Transcription factor TAFII250 promotes Mdm2-dependent turnover of p53. Allende-Vega, N., Saville, M.K., Meek, D.W. Oncogene (2007)
- MDM2-HDAC1-mediated deacetylation of p53 is required for its degradation. Ito, A., Kawaguchi, Y., Lai, C.H., Kovacs, J.J., Higashimoto, Y., Appella, E., Yao, T.P. EMBO J. (2002)
- Analysis of genomic alterations in benign, atypical, and anaplastic meningiomas: toward a genetic model of meningioma progression. Weber, R.G., Boström, J., Wolter, M., Baudis, M., Collins, V.P., Reifenberger, G., Lichter, P. Proc. Natl. Acad. Sci. U.S.A. (1997)
- A TSG101/MDM2 regulatory loop modulates MDM2 degradation and MDM2/p53 feedback control. Li, L., Liao, J., Ruland, J., Mak, T.W., Cohen, S.N. Proc. Natl. Acad. Sci. U.S.A. (2001)
- MDM2 chaperones the p53 tumor suppressor. Wawrzynow, B., Zylicz, A., Wallace, M., Hupp, T., Zylicz, M. J. Biol. Chem. (2007)
- MDM2 and MDMX inhibit the transcriptional activity of ectopically expressed SMAD proteins. Yam, C.H., Siu, W.Y., Arooz, T., Chiu, C.H., Lau, A., Wang, X.Q., Poon, R.Y. Cancer Res. (1999)
- The MDM2 C-terminal region binds to TAFII250 and is required for MDM2 regulation of the cyclin A promoter. Léveillard, T., Wasylyk, B. J. Biol. Chem. (1997)